Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/ijms24108598
Keywords
hepatocellular carcinoma; immunotherapy; liver; liver cancer; immune checkpoint inhibitors; tyrosine kinase inhibitors; locoregional treatment; chemoembolization; TACE; tumor ablation; radioembolization
Ask authors/readers for more resources
Immunotherapy combined with locoregional therapies has revolutionized the treatment of advanced HCC by selectively targeting immune cells and enhancing immunity. This combination has the potential to improve patients' outcomes, reduce recurrence rates, and enhance the efficacy of immunotherapy by altering the tumor immune microenvironment. However, many unanswered questions remain regarding the optimal treatment strategies and patient identification for this combined approach.
Immunotherapy has remarkably revolutionized the management of advanced HCC and prompted clinical trials, with therapeutic agents being used to selectively target immune cells rather than cancer cells. Currently, there is great interest in the possibility of combining locoregional treatments with immunotherapy for HCC, as this combination is emerging as an effective and synergistic tool for enhancing immunity. On the one hand, immunotherapy could amplify and prolong the antitumoral immune response of locoregional treatments, improving patients' outcomes and reducing recurrence rates. On the other hand, locoregional therapies have been shown to positively alter the tumor immune microenvironment and could therefore enhance the efficacy of immunotherapy. Despite the encouraging results, many unanswered questions still remain, including which immunotherapy and locoregional treatment can guarantee the best survival and clinical outcomes; the most effective timing and sequence to obtain the most effective therapeutic response; and which biological and/or genetic biomarkers can be used to identify patients likely to benefit from this combined approach. Based on the current reported evidence and ongoing trials, the present review summarizes the current application of immunotherapy in combination with locoregional therapies for the treatment of HCC, and provides a critical evaluation of the current status and future directions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available